The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.
Mark Kozloff
Honoraria - Lilly
Rocio Carbonero
Honoraria - Lilly (I)
Tamara Nadal
No relevant relationships to disclose
Ivelina Gueorguieva
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Ann Cleverly
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Durisala Desaiah
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michael M. F. Lahn
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sada Pillay
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Al Blunt
Employment or Leadership Position - Covance
Stock Ownership - Covance
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx
Honoraria - Amgen; Merck KGaA; Novartis; Roche; Sanofi
Teresa Macarulla
No relevant relationships to disclose